P., Pan, A., Shin, K., & Lapalombella, R
Peptide protocols typically last 412 weeks, depending on the goal and the peptide prescribed
Tirzepatide amplifies these natural pathways: GLP-1 receptor activation increases insulin secretion in response to meals, suppresses glucagon release (which lowers blood sugar), slows gastric emptying, and reduces appetite through hypothalamic signaling GIP receptor activation enhances insulin sensitivity, may improve fat metabolism, and appears to work synergistically with GLP-1 to produce greater appetite suppression and weight loss than either pathway alone Research published in Cell Metabolism suggests that GIP receptor activation may also influence adipose tissue function and energy expenditure, contributing to tirzepatides superior weight loss outcomes compared to GLP-1-only medications (Samms et al., 2020)
WARNING: NOT FOR USE BY INDIVIDUALS UNDER THE AGE OF 18